Published in Eur J Pharmacol on May 22, 1998
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract (2008) 2.66
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol (2006) 1.94
Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol (2006) 1.44
Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol (2008) 1.42
Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am J Physiol Regul Integr Comp Physiol (2003) 1.30
The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol (2004) 1.18
Role of fesoterodine in the treatment of overactive bladder. Open Access J Urol (2009) 0.87
In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol (2009) 0.87
A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples. Sci Pharm (2011) 0.77
Evidence for a M(1) muscarinic receptor on the endothelium of human pulmonary veins. Br J Pharmacol (2000) 0.76
Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites. Eur J Pharmacol (1986) 0.97
Differences between binding affinities of some antimuscarinic drugs in the parotid gland and those in the urinary bladder and ileum. Acta Pharmacol Toxicol (Copenh) (1983) 0.91
Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology (1999) 0.90
Muscarinic receptor density in the rat urinary bladder after denervation, hypertrophy and urinary diversion. Acta Pharmacol Toxicol (Copenh) (1986) 0.88
Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. Arzneimittelforschung (2001) 0.83
3-(2-Benzofuranyl)quinuclidin-2-ene derivatives: novel muscarinic antagonists. J Med Chem (1996) 0.80
Characterization of the muscarinic cholinoceptors in the human detrusor. J Urol (1985) 0.79
Antimuscarinic 3-(2-furanyl)quinuclidin-2-ene derivatives: synthesis and structure-activity relationships. J Med Chem (1997) 0.78
The effect of phenylpropanolamine on the urethral pressure and heart rate is retained after repeated short-term administration in the unanaesthetized, conscious dog. Scand J Urol Nephrol (1998) 0.77
3-Heteroaryl-substituted quinuclidin-3-ol and quinuclidin-2-ene derivatives as muscarinic antagonists. Synthesis and structure-activity relationships. J Med Chem (1995) 0.76
Air-borne B. subtilis enzymes in the detergent industry. Int Arch Arbeitsmed (1972) 0.75
Muscarinic receptor binding in the parotid gland. Different affinities of some anticholinergic drugs between the parotid gland and ileum. Scand J Gastroenterol Suppl (1982) 0.75
Quinuclidin-2-ene-based muscarinic antagonists. Life Sci (1995) 0.75
Analogues of the muscarinic agent 2'-methylspiro[1-azabicyclo[2.2.2]octane-3,4'-[1,3]dioxolane]: synthesis and pharmacology. J Med Chem (1992) 0.75
On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors. Acta Pharmacol Toxicol (Copenh) (1986) 0.75
Stereoisomers of 3-(2,3-dihydrobenzofuran-2-yl)quinuclidine: preparation and muscarinic receptor affinities. Chirality (1998) 0.75
3-Heteroarylquinuclidin-2-ene derivatives as muscarinic antagonists: synthesis, structure-activity relationships and molecular modelling. Prog Brain Res (1996) 0.75
Muscarinic receptor binding in the guinea pig urinary bladder. Acta Pharmacol Toxicol (Copenh) (1983) 0.75
Pharmacological characterisation of the enantiomers of BM-5, a muscarinic partial agonist with opposed enantioselectivity between affinity and efficacy. Pharmacol Toxicol (2000) 0.75